This feature highlights changes in clinical trial organizations’ personnel.

Alexion Pharmaceuticals

Alexion Pharmaceuticals has named its first chief diversity officer, Uzair Qadeer. Most recently, Qadeer was vice president and head of enterprise partnership at Alexion.

Atea Pharmaceuticals

Atea Pharmaceuticals has named Janet Hammond its new chief development officer. Hammond was most recently vice president of therapeutic area head for general medicine and infectious disease development at AbbVie.

Avacta Life Sciences

Avacta Life Sciences has appointed Neil Bell to the role of chief development officer. Bell was most recently senior vice president and head of clinical operations at Autolus Therapeutics.

Bayer

Lori Moore, a former managing director at Deloitte, has been named vice president and head of pharmaceutical communications at Bayer.

Bellerophon Therapeutics

Board-certified pulmonologist and former senior medical director at Janssen Pharmaceuticals Wassim Fares has been named chief medical officer at Bellerophon Therapeutics.

Bicycle Therapeutics

Dominic Smethurst has been appointed by Bicycle Therapeutics to the role of chief medical officer. Prior to this new position, Smethurst was chief medical officer of Tusk Therapeutics.

Crown Bioscience

Crown Bioscience has named John Gu its new chief operations officer. Formerly, Gu was general manager for China business and chief digital officer at WuXi Nextcode.

Emerald Bioscience

Punit Dhillon has been appointed CEO at Emerald Bioscience. Prior to this appointment, Dhillon was vice president of finance and operations at Inovio Pharmaceuticals.

Entera Bio

Roger Garceau has been named interim CEO of Entera Bio. Garceau has served as a director and chief development adviser at Entera since 2016.

Humanigen

Bob Atwill, current president at Eaton Square, has been named head of Asia-Pacific region at Humanigen. The company has also named Timothy Morris chief operating officer and chief financial officer. Morris previously served as chief financial officer at Iovance.

Jasper Therapeutics

Kevin Heller, former chief medical officer at NextCure, has been named executive vice president of R&D at Jasper Therapeutics.

List Biological Laboratories

List Biological Laboratories has promoted Stacy Burns-Guydish from the role of vice president of biotherapeutic development and manufacturing to the role of company president. List Labs has also named Nancy Shine, the company’s director of R&D, to the role of chief scientific officer. Katherine Shiomoto has been hired by List Labs as its vice president of quality and compliance. Previously, Shiomoto was a vice president of Orchard Therapeutics.

MeiraGTx

Robert Zeldin has been named chief medical officer of MeiraGTx. Zeldin most recently served as chief medical officer of Immunovant.

Moderna

John Lepore has been named senior vice president of government engagement of Moderna. Lepore was most recently general counsel of policy and advocacy at Mastercard.

National Institutes of Health (NIH)

The NIH has nabbed rheumatologist Lindsey Criswell, the current vice chancellor of research at the University of California, San Francisco, to lead the NIH’s National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Nordic Nanovector

Christine Blanc has been named chief medical officer at Nordic Nanovector. Blanc is currently the medical director of Phi-Medics.

Oasmia Pharmaceutical

Peter Selin has been named chief business officer at Oasmia Pharmaceutical. Prior to this appointment, Selin served as vice president of corporate development at Sobi.

PharmaCyte Biotech

José Iglesias has been appointed by PharmaCyte Biotech to the role of consulting chief medical officer for the company’s phase 2b clinical trial in locally advanced, inoperable pancreatic cancer. Iglesias is currently the chief medical officer of Senti Biosciences.

Pharnext

Pharnext’s chief medical officer role has been assumed by Adrian Hepner, the former executive vice president and chief medical officer at Eagle Pharmaceuticals.

PIC Therapeutics

PIC Therapeutics has found its new CEO in Katherine Bowdish, former vice president and head of R&D strategy at Sanofi.

Prometheus Biosciences

Keith Marshall has been named chief medical officer of Prometheus Biosciences. Most recently, Marshall was executive vice president, chief operating officer and chief financial officer of Conatus Pharmaceuticals.

Sierra Oncology

Kevin Norrett has been appointed chief business officer of Sierra Oncology. Sierra has also appointed William Turner to the role of chief regulatory and technical operations officer. Turner was most recently the senior vice president of technical operations and regulatory science at Aimmune Therapeutics.

Spark Therapeutics

Former Genentech vice president Gallia Levy has been named chief medical officer of Spark Therapeutics.

StrideBio

William Monteith has been named chief operating officer of StrideBio. Prior to joining StrideBio, Monteith was executive vice president of technical operations at Cellectis.

Terns Pharmaceuticals

Terns Pharmaceuticals has appointed Senthil Sundaram to CEO, Mark Vignola to chief financial officer and Erin Quirk to president. Prior to joining Terns, Sundaram was chief financial officer at Nightstar Therapeutics. Vignola and Quirk previously served as chief financial officer of Applied Therapeutics and vice president of clinical research at Gilead Sciences, respectively.

TopAlliance Biosciences

Patricia Keegan has been tapped by TopAlliance Biosciences to take on the role of chief medical officer. Keegan joined the company from the FDA, where she served as acting associate director of medical policy for the Oncology Center of Excellence.

Valneva

Juan Jaramillo has been named chief medical officer of Valneva. Prior to this role, Jaramillo held various positions at GlaxoSmithKline, Daiichi Sankyo and Grünenthal.

WuXi Vaccines

WuXi Vaccines has appointed Jian Dong to be its CEO. Dong was most recently responsible for the company’s global biomanufacturing, global engineering and the overall operations.

XORTX Therapeutics

XORTX Therapeutics has hired David Sans as the company’s director of corporate development. Sans previously held management and executive positions at Pfizer, Novartis and ImClone.